Statistics in clinical trials

Stephanie J. Green, Donna K. Pauler

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Statistical developments over the past several years are described in this review. Efforts in phase I studies have focused on efficient estimation of maximum tolerated dose. Issues investigated for phase II trials include incorporation of multiple endpoints and randomization. For phase III trials, methods to reduce time or use the sample size more efficiently have been investigated. However, design innovations come with costs, including possible increased risk of incorrect conclusions. Other recent challenging statistical developments in clinical trials relate to use of complementary outcomes such as quality of life and to associated biologic questions, including the emergence of the field of genomics.

Original languageEnglish (US)
Pages (from-to)36-41
Number of pages6
JournalCurrent Oncology Reports
Volume6
Issue number1
DOIs
StatePublished - Jan 2004

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Statistics in clinical trials'. Together they form a unique fingerprint.

Cite this